Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201013
Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest.
Matèries
Matèries (anglès)
Citació
Citació
BOUZAS, Cristina, PASTOR, Rosario, GARCÍA, Silvia, MONSERRAT-MESQUIDA, Margalida, MARTÍNEZ-GONZÁLEZ, Miguel ángel, SALAS SALVADÓ, Jordi, CORELLA PIQUER, Dolores, GODAY ARNÓ, Albert, MARTÍNEZ, J. alfredo, ALONSO GÓMEZ, Ángel m., FERNÁNDEZ-BARCELÓ, Olga, VIOQUE, Jesús, ROMAGUERA, Dora, LÓPEZ MIRANDA, José, ESTRUCH RIBA, Ramon, TINAHONES, Francisco j., LAPETRA, José, SERRA MAJEM, Lluís, RIQUELME GALLEGO, Blanca, MARTÍN SÁNCHEZ, Vicente, PINTÓ SALA, Xavier, DELGADO RODRIGUEZ, Miguel, MATÍA MARTÍN, Pilar, VIDAL I CORTADA, Josep, CARDENAS-SALAS, Jersy-jair, DAIMIEL, Lidia, ROS RAHOLA, Emilio, TOLEDO ATUCHA, Estefanía, MANZANARES, Josep-maria, GONZALEZ MONGE, Inmaculada, MUÑOZ PÉREZ, Miguel ángel, MARTINEZ-URBISTONDO, Diego, TOJAL SIERRA, Lucas, MUÑOZ BRAVO, Carlos, MIRALLES GISBERT, Salvador, MARTIN, Marian, GARCÍA RÍOS, Antonio, CASTRO-BARQUERO, Sara, FERNÁNDEZ GARCÍA, José c., SANTOS LOZANO, José manuel, BASTERRA GORTARI, F. javier, GUTIÉRREZ CARRASQUILLA, Liliana, GUILLEM SAIZ, Patricia, SATORRES, Alba, ABETE, Itziar, SORTO SANCHEZ, Carolina, DÍEZ ESPINO, Javier, BABIO, Nancy, FITÓ COLOMER, Montserrat, TUR, Josep a.. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome.. _Biomedicine & Pharmacotherapy_. 2023. Vol. 161, núm. 114561. [consulta: 23 de gener de 2026]. ISSN: 0753-3322. [Disponible a: https://hdl.handle.net/2445/201013]